Sign In
Get Clay Free →

Suggestions

    David Haylock

    CEO at VivaZome Therapeutics

    Professional Background

    David Haylock currently serves as the Chief Scientific Officer (CSO) at VivaZome Therapeutics, a prominent role he has held since 2018. At VivaZome, he is at the forefront of developing innovative exosome-based therapies aimed at treating serious diseases, harnessing years of experience in the field of medical research. David's illustrious career spans over 45 years, beginning in the Haematology Department of the Institute of Medical and Veterinary Science (IMVS) in Adelaide. Here, he collaborated with esteemed colleagues Chris Juttner and Bik To to pioneer mobilized blood stem cell transplantation, marking a significant milestone in hematological research.

    David's tenure at the Leukaemia Research Unit saw him focus on ex vivo manipulation of human hematopoietic stem and progenitor cells, an endeavor that culminated in receiving the prestigious Albert Baikie Memorial Medal. This award recognized his groundbreaking research on enumerating blood CD34+ cell levels, which has become a standard method for scheduling stem cell apheresis.

    In 2000, David transitioned to the Peter MacCallum Cancer Centre in Melbourne, where he took on the role of Head of Experimental Cell Therapy. Here, in collaboration with Miles Prince, he successfully conducted Australia's first clinical study using ex vivo expanded blood CD34+ cells, produced within a Good Manufacturing Practice (GMP) facility. This significant achievement not only advanced clinical practices but also established new protocols for stem cell therapies in Australia.

    David's career continued to flourish when he was appointed Director of the Major National Research Facility at the Australian Stem Cell Centre in 2005. This pivotal role allowed him to contribute significantly to stem cell research on a national scale. In 2009, he further enhanced his leadership profile by taking on the position of OCE Science Leader at CSIRO (Commonwealth Scientific and Industrial Research Organisation), where he currently serves as the Cell Biology Group Leader. David's research impacts a variety of fields, particularly cell-material interactions, biomaterials, stem cell therapy, and biosensor technology.

    Throughout his esteemed career, David has consulted and collaborated with numerous esteemed organizations within the industry, including Baxter Healthcare, Gambro BCT, Dynal, CellPro, Miltenyi Biotech, Bresagen, Johnson and Johnson, Cynata, and Coulter. His breadth of experience has positioned him as a thought leader and innovator in the regenerative medicine space.

    Education and Achievements

    David Haylock's academic journey has been instrumental in shaping his extensive knowledge and expertise in the medical research realm. He pursued advanced studies at notable institutions, laying the foundation for his prolific career. While specific details of his educational history are currently unavailable, it's evident that his education has complemented his research endeavors remarkably well.

    His achievements include being awarded the Albert Baikie Memorial Medal, recognition of his significant contribution to the field of hematology through his pioneering work on CD34+ levels and stem cell apheresis scheduling. Additionally, as Head of Experimental Cell Therapy at the Peter MacCallum Cancer Centre, David's leadership was pivotal in driving innovative clinical studies, further solidifying his status in the medical research community.

    Current Research Interests

    David's research interests are dynamic and reflect the evolving landscape of regenerative medicine. His current focus areas include:

    • Cell-material interactions: Understanding how cells interact with various materials is vital for developing innovative therapies and technologies that enhance patient outcomes.
    • Biomaterials: Research in this field aims to create materials that support and enhance cellular functions, paving the way for advanced medical applications.
    • Stem cell therapy: Continued exploration of stem cell applications holds the promise to unlock new treatment protocols for numerous medical conditions.
    • Biosensor technology: Development in biosensors will facilitate real-time monitoring and diagnostics, ultimately improving patient management in clinical settings.

    Professional Affiliations

    In addition to his role at VivaZome Therapeutics, David holds the esteemed position of Adjunct Professor with the Australian Regenerative Medicine Institute at Monash University. This affiliation underscores his commitment to education and mentorship within the field of regenerative medicine, further enhancing the knowledge base available to the upcoming generation of scientists.

    Conclusion

    David Haylock has undoubtedly made significant contributions to medical research, particularly in the areas of hematology, stem cell therapy, and regenerative medicine. His leadership roles and innovative contributions at leading institutions have paved the way for advancements that benefit not only the scientific community but also patients facing serious medical challenges. As the field continues to evolve, David's work at VivaZome Therapeutics and beyond highlights the potential for exosome-based therapies to revolutionize treatment methodologies. With a career enriched by collaboration, innovation, and a commitment to science, David Haylock stands as an exemplary figure in the medical research landscape.

    tags:[

    medical research

    chief scientific officer

    stem cell therapy

    exosome therapies

    haematology

    cell biology

    biomaterials

    biosensor technology

    introduction to regenerative medicine

    Peter MacCallum Cancer Centre

    CSIRO

    VivaZome Therapeutics

    Albert Baikie Memorial Medal

    Adjunct Professor

    collaborative research

    Related Questions

    How did David Haylock's pioneering work in mobilized blood stem cell transplantation influence current stem cell therapies?
    What inspired David Haylock to focus his research on exosome-based therapies at VivaZome Therapeutics?
    How has David Haylock's collaboration with industry leaders shaped advancements in stem cell therapy?
    In what ways does David Haylock's role as Adjunct Professor at Monash University enhance his contributions to regenerative medicine?
    What are David Haylock's future research goals in the areas of biomaterials and biosensor technology?
    D
    Add to my network